17 / 42
Pain Management 2018
Internal Medicine 2018
International Journal of Anesthesiology & Pain Medicine
ISSN: 2471-982X
Page 68
March 26-28, 2018
Vienna, Austria
JOINT EVENT
7
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Internal Medicine and Patient Care
&
6
t h
E d i t i o n o f I n t e r n a t i o n a l C o n f e r e n c e o n
Pain Management
Volume 4
Background:
Two oral antifungal agents, griseofulvin and
terbinafine, have regulatory approval but it is unknown whether
one has superior overall efficacy. Genus-specific differences in
efficacy are believed to exist for the two agents. It is not clear at
what doses and durations of treatment these differences apply.
Purpose:
The purposes of this meta-analysis were to determine
whether a statistically significant difference in efficacy exists
between these agents at a given dose and duration of each in
tinea capitis infections overall and to determine whether a genus-
specific difference in efficacy exists for these two treatments
at a given dose and duration of each. We performed a literature
search for clinically and methodologically similar randomized
controlled trials comparing 8 weeks of griseofulvin (6.25–12.5
mg⁄kg⁄day) to 4 weeks of terbinafine (3.125–6.25 mg⁄kg⁄day)
in the treatment of tinea capitis. A meta-analysis was performed
using the Mantel–Haenszel method and random effects model;
results were expressed as odds ratios with 95%.
Results:
Meta-analysis of randomized controlled trials did not
show a significant difference in the overall efficacy of the two
drugs at the doses specified, but specific efficacy differences
were observed based on the infectious species. For tinea capitis
caused by Microsporum spp., griseofulvin is superior (p=0.04),
whereas terbinafine is superior for Trichophyton spp. infection
(p=0.04).
Conclusion:
Our results support species-specific differences
in treatment efficacy between griseofulvin and terbinafine and
provide a clinical context in which this knowledge may be applied.
Biography
Nawal HatemHerzallah has completed her Medical Degree from Royal Col-
lege of Surgeons in Ireland, Dublin. She is currently a Medical Intern at King
Fahd Hospital of the University in Khobar, Saudi Arabia.
nawalhherzallah@hotmail.comGriseofulvin vs. terbinafine in the treatment of tinea capitis
Nawal Hatem Herzallah
1
, Humoud Mansour AlKhalaf
1
, Adnan Meteb Mohamed Al-
mezani
2
, Youssef Mohammad Almodhaibri
3
, Mustafa Mohamed Ali Almusallami
4
,
Jumanh Khalid Attiah
5
, Abdulaziz Mohammed Alsahli
6
, Maha Fahad Alluqmani
5
,
Fatimah Mohammed Saeedi
5
, Ali Hassan Jaber Alzahrani
7
, Ibrahim Abdullah Al
Taha
8
, Somaya Khalid Alsharif
9
and
Fatema Hassan A ALAjwad
10
1
Royal College of Surgeons in Ireland, Ireland
2
Hail university, Saudi Arabia
3
Qassim University, Saudi Arabia
4
Hera General Hospital, Saudi Arabia
5
Ibn Sina National College, Saudi Arabia
6
King Abdulaziz University, Saudi Arabia
7
King Abdulaziz University, Rabigh, Saudi Arabia
8
Oyun City Hospital, Saudi Arabia
9
Umm Al-Qura University, Saudi Arabia
10
Imam Abdulrahman Bin Faisal University, Saudi Arabia
Nawal Hatem Herzallah et al., Int J Anesth Pain Med 2018, Volume 4
DOI: 10.21767/2471-982X-C1-003